Company registration number 14804724 (England and Wales)
PHARMAQM LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025
PAGES FOR FILING WITH REGISTRAR
PHARMAQM LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
PHARMAQM LIMITED
BALANCE SHEET
AS AT
30 APRIL 2025
30 April 2025
- 1 -
2025
2024
Notes
£
£
£
£
Current assets
Debtors
3
15,683
13,686
Cash at bank and in hand
40,204
83,941
55,887
97,627
Creditors: amounts falling due within one year
4
(18,602)
(38,298)
Net current assets
37,285
59,329
Capital and reserves
Called up share capital
5
1
1
Profit and loss reserves
37,284
59,328
Total equity
37,285
59,329

For the financial year ended 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 28 July 2025
G Rendle
Director
Company registration number 14804724 (England and Wales)
PHARMAQM LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025
- 2 -
1
Accounting policies
Company information

PharmaQM Limited is a private company limited by shares incorporated in England and Wales. The registered office is Suites C, D, E & F, 14th Floor, The Plaza, 100 Old Hall Street, Liverpool, L3 9QJ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

1.3
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.4
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

PHARMAQM LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
1
Accounting policies
(Continued)
- 3 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.5
Retirement benefits
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
1
1
3
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
15,568
13,503
Other debtors
115
183
15,683
13,686
4
Creditors: amounts falling due within one year
2025
2024
£
£
Corporation tax
15,794
35,894
Other taxation and social security
77
-
0
Other creditors
2,731
2,404
18,602
38,298
PHARMAQM LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
- 4 -
5
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
of £1 each
1
1
1
1
2025-04-302024-05-01falsefalsefalse28 July 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityG Rendle148047242024-05-012025-04-30148047242025-04-30148047242024-04-3014804724core:CurrentFinancialInstrumentscore:WithinOneYear2025-04-3014804724core:CurrentFinancialInstrumentscore:WithinOneYear2024-04-3014804724core:ShareCapital2025-04-3014804724core:ShareCapital2024-04-3014804724core:RetainedEarningsAccumulatedLosses2025-04-3014804724core:RetainedEarningsAccumulatedLosses2024-04-3014804724core:ShareCapitalOrdinaryShareClass12025-04-3014804724core:ShareCapitalOrdinaryShareClass12024-04-3014804724bus:Director12024-05-012025-04-30148047242023-04-152024-04-3014804724core:CurrentFinancialInstruments2025-04-3014804724core:CurrentFinancialInstruments2024-04-3014804724core:WithinOneYear2025-04-3014804724core:WithinOneYear2024-04-3014804724bus:OrdinaryShareClass12024-05-012025-04-3014804724bus:OrdinaryShareClass12025-04-3014804724bus:OrdinaryShareClass12024-04-3014804724bus:PrivateLimitedCompanyLtd2024-05-012025-04-3014804724bus:SmallCompaniesRegimeForAccounts2024-05-012025-04-3014804724bus:FRS1022024-05-012025-04-3014804724bus:AuditExemptWithAccountantsReport2024-05-012025-04-3014804724bus:FullAccounts2024-05-012025-04-30xbrli:purexbrli:sharesiso4217:GBP